OBJECTIVE: An unconventional population of CD4+ signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxic effector memory T (TEM ) cells (CD4+ cytotoxic T lymphocytes [CTLs]) has been linked causally to IgG4-related disease (IgG4-RD). Glucocorticoids represent the first-line therapeutic approach in patients with IgG4-RD, but their mechanism of action in this specific condition remains unknown. We undertook this study to determine the impact of glucocorticoids on CD4+ CTLs in IgG4-RD. METHODS: Expression of CD8α, granzyme A, perforin, and SLAMF7 within the effector memory compartment of CD45RO+ (TEM ) and CD45RA+ effector memory T (TEMRA ) CD4+ cells was quantified by flow cytometry in 18 patients with active IgG4-RD, both at baseline and after 6 months of glucocorticoid treatment. Eighteen healthy subjects were studied as controls. Next-generation sequencing of the T cell receptor α- and β-chain gene was performed on circulating CD4+ CTLs from patients with IgG4-RD before and after treatment and in affected tissues. RESULTS: Circulating CD4+ TEM and TEMRA cells were not expanded in IgG4-RD patients compared to healthy controls. CD4+SLAMF7+ TEM cells (but not TEMRA cells) were significantly increased among IgG4-RD patients. Within CD4+SLAMF7+ TEM cells, CD8α- cells but not CD8αlow cells were elevated in IgG4-RD patients. The same dominant clones of CD8α-CD4+SLAMF7+ TEM cells found in peripheral blood were also identified in affected tissue. CD8α- and CD8αlow CD4+SLAMF7+ TEM cells both expressed cytolytic molecules. Clonally expanded CD8α- but not CD8αlow CD4+SLAMF7+ TEM cells decreased following glucocorticoid-induced disease remission. CONCLUSION: A subset of CD8α-CD4+SLAMF7+ cytotoxic TEM cells is oligoclonally expanded in patients with active IgG4-RD. This TEM cell population contracts following glucocorticoid-induced remission. Further characterization of this cell population may provide prognostic information and targets for therapeutic intervention.
OBJECTIVE: An unconventional population of CD4+ signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxiceffector memory T (TEM ) cells (CD4+ cytotoxic T lymphocytes [CTLs]) has been linked causally to IgG4-related disease (IgG4-RD). Glucocorticoids represent the first-line therapeutic approach in patients with IgG4-RD, but their mechanism of action in this specific condition remains unknown. We undertook this study to determine the impact of glucocorticoids on CD4+ CTLs in IgG4-RD. METHODS: Expression of CD8α, granzyme A, perforin, and SLAMF7 within the effector memory compartment of CD45RO+ (TEM ) and CD45RA+ effector memory T (TEMRA ) CD4+ cells was quantified by flow cytometry in 18 patients with active IgG4-RD, both at baseline and after 6 months of glucocorticoid treatment. Eighteen healthy subjects were studied as controls. Next-generation sequencing of the T cell receptor α- and β-chain gene was performed on circulating CD4+ CTLs from patients with IgG4-RD before and after treatment and in affected tissues. RESULTS: Circulating CD4+ TEM and TEMRA cells were not expanded in IgG4-RD patients compared to healthy controls. CD4+SLAMF7+ TEM cells (but not TEMRA cells) were significantly increased among IgG4-RD patients. Within CD4+SLAMF7+ TEM cells, CD8α- cells but not CD8αlow cells were elevated in IgG4-RD patients. The same dominant clones of CD8α-CD4+SLAMF7+ TEM cells found in peripheral blood were also identified in affected tissue. CD8α- and CD8αlow CD4+SLAMF7+ TEM cells both expressed cytolytic molecules. Clonally expanded CD8α- but not CD8αlow CD4+SLAMF7+ TEM cells decreased following glucocorticoid-induced disease remission. CONCLUSION: A subset of CD8α-CD4+SLAMF7+ cytotoxic TEM cells is oligoclonally expanded in patients with active IgG4-RD. This TEM cell population contracts following glucocorticoid-induced remission. Further characterization of this cell population may provide prognostic information and targets for therapeutic intervention.
Authors: C Campochiaro; G A Ramirez; E P Bozzolo; M Lanzillotta; A Berti; E Baldissera; L Dagna; L Praderio; R Scotti; M Tresoldi; L Roveri; A Mariani; G Balzano; R Castoldi; C Doglioni; M G Sabbadini; E Della-Torre Journal: Scand J Rheumatol Date: 2015-09-23 Impact factor: 3.641
Authors: Emanuel Della-Torre; Eoin Feeney; Vikram Deshpande; Hamid Mattoo; Vinay Mahajan; Maria Kulikova; Zachary S Wallace; Mollie Carruthers; Raymond T Chung; Shiv Pillai; John H Stone Journal: Ann Rheum Dis Date: 2014-08-20 Impact factor: 19.103
Authors: Anna E Oja; Felipe A Vieira Braga; Ester B M Remmerswaal; Natasja A M Kragten; Kirsten M L Hertoghs; Jianmin Zuo; Paul A Moss; René A W van Lier; Klaas P J M van Gisbergen; Pleun Hombrink Journal: Front Immunol Date: 2017-03-24 Impact factor: 7.561
Authors: Eliana Ruggiero; Jan P Nicolay; Raffaele Fronza; Anne Arens; Anna Paruzynski; Ali Nowrouzi; Gökçe Ürenden; Christina Lulay; Sven Schneider; Sergij Goerdt; Hanno Glimm; Peter H Krammer; Manfred Schmidt; Christof von Kalle Journal: Nat Commun Date: 2015-09-01 Impact factor: 14.919
Authors: Hugues Allard-Chamard; Faisal Alsufyani; Naoki Kaneko; Kelly Xing; Cory Perugino; Vinay S Mahajan; Joseph L Wheat; George S Deepe; James Loyd; Shiv Pillai Journal: J Immunol Date: 2020-12-16 Impact factor: 5.422